Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	1.02	0.01	-0.00881	1.0	1.0
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	1.0	0.01	-0.101	1.0	0.956
BT-20	TGX221	3	72	flat	flat	BT20 TGX-221 0 3 72	8	2.469	Inf	1.01	0.0147	1.01	0.01	-0.0563	1.0	0.982	Inf	1.01	0.983	1.01	0.01	-0.0552	1.0	0.979
BT-20	Everolimus	3	72	flat	flat	BT20 everolimus 0 3 72	8	2.422	Inf	0.475	0.456	0.475	0.01	0.602	0.0632	0.543	Inf	0.478	0.534	0.478	0.01	0.561	0.0844	0.534
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	1.03	0.01	-0.588	1.0	1.02
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	1.03	0.01	-0.587	1.0	1.02
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.981	0.01	-0.0553	1.0	0.972
HCC1806	KIN001-244	3	72	flat	flat	HCC1806 KIN001-244 0 3 72	8	3.195	Inf	0.988	0.0203	0.988	0.01	-0.0575	1.0	0.982	Inf	0.981	0.968	0.981	0.01	-0.0553	1.0	0.972
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	1.0	0.01	-1.16	1.0	1.02
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.634	0.01	0.541	0.0969	0.833
BT-20	BX-912	1	72	flat	flat	BT20 BX-912 0 1 72	8	2.193	Inf	0.858	0.0928	0.858	0.01	0.25	0.422	0.903	Inf	0.851	0.901	0.851	0.01	0.243	0.433	0.897
BT-549	Alpelisib	1	72	flat	flat	BT549 alpelisib 0 1 72	8	1.822	Inf	0.747	0.0781	0.747	0.01	0.439	0.176	0.914	Inf	0.782	0.931	0.782	0.01	0.415	0.2	0.925
BT-549	Everolimus	2	72	flat	flat	BT549 everolimus 0 2 72	8	1.909	Inf	0.566	0.407	0.566	0.01	-0.646	1.0	0.594	Inf	0.627	0.648	0.627	0.01	-1.01	1.0	0.649
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.813	0.01	0.383	0.234	0.937
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.796	0.01	-0.00637	1.0	0.92
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.708	0.01	0.0505	0.856	0.857
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.946	0.01	-0.0808	1.0	0.958
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.968	0.01	-0.000878	1.0	1.0
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.879	0.01	0.00619	0.982	0.896
HCC38	Alpelisib	1	72	flat	flat	HCC38 alpelisib 0 1 72	8	1.738	Inf	0.757	0.0835	0.757	0.01	0.593	0.0674	0.909	Inf	0.798	0.929	0.798	0.01	0.579	0.0744	0.923
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.914	0.01	0.418	0.197	0.951
Hs 578T	XL147	3		flat	flat	Hs578T pilaralisib 3	8	2.879	Inf	0.971	-0.00618	0.971	0.01	0.331	0.299	1.0	Inf	0.959	1.01	0.959	0.01	0.319	0.315	1.0
Hs 578T	XL147	2		flat	flat	Hs578T pilaralisib 2	8	2.509	Inf	0.976	0.000255	0.976	0.01	0.435	0.181	0.997	Inf	0.97	1.0	0.97	0.01	0.432	0.183	0.996

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)